Physician profile
Attri Datta
NPI 1730471236
$7,324.13
in general payments reported to CMS, 2019-2025
33 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $71.15 · 2021: $351 · 2022: $892 · 2023: $986 · 2024: $2,492 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,296 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,296.35 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,547.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,439.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $682.01 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $646.46 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $519.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Antares Pharma, INC. | $407.43 | 2019-2025 | Xyosted |
| Astellas Pharma US INC | $320.02 | 2024-2025 | Veozah |
| Pfizer INC. | $307.23 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.93 | 2021-2025 | Jardiance |
| Dexcom, INC. | $173.94 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $154.98 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $94.34 | 2023-2025 | Repatha, Otezla, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $71.52 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.13 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $54.17 | 2025 | Gemtesa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $53.58 | 2024-2025 | Tlando |
| Boston Scientific Corporation | $51.92 | 2025 | General - Pain Management |
| Dynavax Technologies Corporation | $51.41 | 2024 | Heplisav-B |
| Globus Medical, INC. | $50.20 | 2025 | Senza |
| Merck Sharp & Dohme LLC | $49.05 | 2022-2024 | Gardasil, Gardasil 9, Capvaxive |
| Idorsia Pharmaceuticals US INC | $48.73 | 2024 | Quviviq |
| Inspire Medical Systems, INC. | $37.73 | 2025 | Inspire |
| Biotronik Nro, INC. | $36.86 | 2024-2025 | Prospera |
| Allergan, INC. | $36.62 | 2019 | |
| Abbott Laboratories | $35.75 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $34.62 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $27.84 | 2023-2025 | Contrave, Onzetra Xsail |
| Vivus LLC | $24.17 | 2023 | Qsymia |
| Novartis Pharmaceuticals Corporation | $22.18 | 2019 | |
| Philips North America LLC | $21.11 | 2024 | (Ck7) Extended Holter |
| Halozyme INC | $19.91 | 2023 | |
| Nevro Corp. | $17.20 | 2024 | Senza |
| Clarus Therapeutics INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Attri Datta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.